(Reuters) – The European Medicines Agency backed the use of Novo Nordisk’s Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.
The company expects the EU label update for expanded use of Wegovy will be implemented shortly. The update will allow the drug to be given to patients suffering from obesity-related heart failure with preserved ejection fraction (HFpEF).
The update is based on data from late-stage studies in which Wegovy helped reduce symptoms of the disease and improved physical limitations and exercise function in patients.
Earlier this year, the EU regulator also backed use of Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)
Comments